12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Monoclonal antibody successes in the clinic.

      Nature biotechnology
      Animals, Antibodies, Monoclonal, chemistry, therapeutic use, Biotechnology, methods, trends, Chemistry, Pharmaceutical, Clinical Trials as Topic, Drug Approval, Drug Industry, Humans, Hybridomas, metabolism, Immunotherapy, Neoplasms, therapy, United States, United States Food and Drug Administration

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.

          Related collections

          Author and article information

          Comments

          Comment on this article